Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds
In a small study, 140 youngsters who’d already gotten two shots were given a booster six months later, and researchers found the extra shot generally revved up their immune response. But a closer look at 30 of the children found a 36-fold increase in virus-fighting antibodies, levels high enough to fight the super-contagious omicron variant, Pfizer and its partner BioNTech said in a press release.
The data has not been published or vetted by independent experts.
Pfizer tested the kid booster while omicron was surging this winter. While COVID-19 cases now are at much lower levels in the U.S., in recent weeks an even more contagious version of omicron, called BA.2, has become the dominant type locally and around the world.
In the coming days, the companies plan to ask the U.S. Food and Drug Administration to authorize a booster for healthy 5- to 11-year-olds. They also plan to share the data with European and other regulators.
The Pfizer shots are the only vaccine available to U.S. children. Those ages 5 to 11 receive one-third of the dose given to everyone 12 and older. Just over a quarter in the younger age group have gotten two doses since vaccination opened to them in November, shortly before omicron struck.
The U.S. hasn’t yet allowed vaccinations for children under 5. But certain 5- to 11-year-olds — those with severely weakened immune systems — already are supposed to get three doses, to give that high-risk group a better chance of responding.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.